As India’s contract manufacturing and development organization (CDMO) is set to double in the next decade, Anthem Biosciences ...

Anthem Biosciences, an India-based CDMO, submitted a filing (PDF) at the end of 2024 to announce its plans for a 33.95 ...

Anthem Biosciences on Tuesday (December 31 ... The proposed initial public offer (IPO) is entirely an offer for sale (OFS) worth ₹3,395 crore by promoters, investors and other selling ...

Contract research company Anthem Biosciences has filed for a Rs 3,395 ... The selling shareholders will be entitled to the proceeds from the IPO and the company will not receive any proceeds ...

(Reuters) -Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion ... are among investors who will sell shares in the IPO. The company will not sell any shares and it did not ...

Indian contract drugmaker Anthem Biosciences filed for a ₹3,395 crore ... are among the investors who will sell shares in the IPO. The company will not sell shares and did not give any other ...

Indian drugmaker Anthem Biosciences filed for a 33.95-billion-rupee ($397 million) initial public offering, draft papers showed on Tuesday. Anthem will not issue new shares in the IPO. ($1 = 85.5720 I ...

Since the IPO is entirely an OFS, the company will not receive any ... Suven Life Sciences and Divi's Laboratories are the listed peers of Anthem Biosciences, as per the DRHP. JM Financial Ltd, ...